Poniard Pharmaceuticals Inc (PARD)

Poniard Pharmaceuticals Inc is a biotechnology company listed on OTC Markets under the ticker PARD. The company focuses on developing and commercializing cancer therapeutics, with Picoplatin identified as its lead product candidate. Picoplatin is a platinum-based therapy that has been evaluated across several cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. Poniard has advanced the candidate through clinical testing, including a pivotal Phase III SPEAR trial in second-line small cell lung cancer, Phase II studies in metastatic colorectal cancer and castration-resistant prostate cancer, and a Phase I study of an oral formulation in solid tumors. Founded in 1984 and based in Seattle, Washington, the company was previously known as NeoRx Corporation before adopting its current name in 2006.

Jump directly to the stock analysis sections supported by the latest available data.